The stock of Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) is a huge mover today! The stock increased 3.83% or $0.34 on November 23, hitting $9.22. About 97,133 shares traded hands. Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) has risen 28.59% since April 22, 2016 and is uptrending. It has outperformed by 23.18% the S&P500.
The move comes after 5 months positive chart setup for the $328.93 million company. It was reported on Nov, 24 by Barchart.com. We have $10.05 PT which if reached, will make NASDAQ:FOMX worth $29.60M more.
Analysts await Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) to report earnings on March, 2. They expect $-0.32 earnings per share, down 88.24% or $0.15 from last year’s $-0.17 per share. After $-0.19 actual earnings per share reported by Foamix Pharmaceuticals Ltd for the previous quarter, Wall Street now forecasts 68.42% negative EPS growth.
According to Zacks Investment Research, “Foamix Pharmaceuticals Ltd. is a specialty pharmaceutical company. It develops and commercializes foam-based formulations acne, impetigo, and other skin conditions. The Company’s lead product candidates include FMX101, which has completed a dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo. It has operations primarily in the United States, Germany, and Israel. Foamix Pharmaceuticals Ltd. is headquartered in Rehovot, Israel.”
More notable recent Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) news were published by: Prnewswire.com which released: “Foamix Pharmaceuticals Ltd. Announces Proposed Follow-on Offering of Ordinary …” on September 27, 2016, also Prnewswire.com with their article: “Foamix Pharmaceuticals to Present at the 25th Annual Credit Suisse Healthcare …” published on November 03, 2016, Quotes.Wsj.com published: “News Foamix Pharmaceuticals Ltd.FOMX” on September 13, 2014. More interesting news about Foamix Pharmaceuticals Ltd (NASDAQ:FOMX) were released by: Marketwatch.com and their article: “/quotes/zigman/3870025/realtime” published on September 19, 2014 as well as Schaeffersresearch.com‘s news article titled: “Analyst Update: Foamix Pharmaceuticals Ltd, Jazz Pharmaceuticals plc, and …” with publication date: August 10, 2016.
FOMX Company Profile
Foamix Pharmaceuticals Ltd., incorporated on January 19, 2003, is a clinical-stage specialty pharmaceutical company. The Firm is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea, impetigo and other skin conditions. The Firm operates in the segment of development and commercialization of foam formulations.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.